Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

52.8K
Overview
52.8K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

351
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
351
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

1.6K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and immunogenicity of concomitant quadrivalent meningococcus ACYW-TT and meningococcus group B vaccines.

NPJ vaccines·2026
Same author

Large outbreak of group B invasive meningococcal disease in young adults in South East England, March 2026.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026
Same author

Lower incidence and higher case fatality rates associated with invasive meningococcal disease during COVID-19 pandemic restrictions (March 2020 to July 2021) in England.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Meningococcal disease, meningococcal vaccines, and the recent meningococcal outbreak in Kent, UK.

The Lancet. Infectious diseases·2026
Same author

Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial.

The Lancet. Infectious diseases·2026
Same author

Strengthening regional surveillance: MenMap Network's year 1 findings on bacterial meningitis in Jordan, Egypt, and Iraq (2023-2024).

IJID regions·2026
Same journal

Eugenol nanoparticle as a therapeutic agent against Pseudomonas infection in mice.

Pathogens and disease·2025
Same journal

Akkermansia muciniphila attenuates sepsis-induced immunosuppression by shaping endotoxin-tolerant macrophage phenotypes.

Pathogens and disease·2025
Same journal

Inc/GFP chimera protein-based interactomics reveals host cellular interactions of Cps0558, a novel Chlamydia psittaci inclusion protein.

Pathogens and disease·2025
Same journal

Primary human nasal, nasopharyngeal, and bronchial epithelia show distinct immune responses to various pathogens.

Pathogens and disease·2025
Same journal

Expression of Concern: Blockade of interleukin-17A protects against coxsackievirus B3-induced myocarditis by increasing COX-2/PGE2 production in the heart.

Pathogens and disease·2025
Same journal

Expression of Concern: Protective effects of Lactobacillus rhamnosus GG against human rotavirus-induced diarrhoea in a neonatal mouse model.

Pathogens and disease·2025
See all related articles

Related Experiment Video

Updated: Mar 5, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

11.4K

Does post-implementation vaccine effectiveness data support pre-implementation predictions of 4CMenB utility?

Jamie Findlow, Ray Borrow

    Pathogens and Disease
    |March 24, 2017
    PubMed
    Summary
    This summary is machine-generated.

    New meningococcal serogroup B vaccines (4CMenB) show effectiveness in infants. This study re-evaluates correlates of protection using phenotypic and genotypic data from invasive MenB disease cases.

    Keywords:
    4CMenBNeisseria meningitidismeningococcalvaccinevaccine effectiveness

    More Related Videos

    Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle
    15:57

    Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle

    Published on: July 11, 2015

    12.8K
    Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
    06:26

    Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

    Published on: July 28, 2023

    3.2K

    Related Experiment Videos

    Last Updated: Mar 5, 2026

    Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
    08:52

    Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

    Published on: February 22, 2019

    11.4K
    Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle
    15:57

    Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle

    Published on: July 11, 2015

    12.8K
    Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
    06:26

    Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

    Published on: July 28, 2023

    3.2K

    Area of Science:

    • Vaccinology
    • Immunology
    • Microbiology

    Background:

    • Meningococcal serogroup B vaccines (4CMenB) are licensed based on safety and immunogenicity, not efficacy studies.
    • Assessing vaccine coverage breadth is challenging, relying on correlates of protection like serum bactericidal antibody and novel assays.
    • The meningococcal antigen typing system is a novel assay used to evaluate vaccine effectiveness.

    Purpose of the Study:

    • To re-evaluate correlates of protection for meningococcal serogroup B vaccines.
    • To assess the effectiveness of 4CMenB in a reduced infant dose schedule.
    • To utilize phenotypic and genotypic information from invasive MenB disease cases.

    Main Methods:

    • Review of data on the effectiveness of 4CMenB in infants.
    • Analysis of phenotypic and genotypic information from invasive MenB disease isolates and sera.
    • Evaluation of correlates of protection, including serum bactericidal antibody and meningococcal antigen typing system.

    Main Results:

    • Demonstration of the effectiveness of 4CMenB in a reduced infant dose schedule.
    • Gathering of detailed phenotypic and genotypic information from invasive MenB disease cases in vaccine-eligible infants.
    • Enabling a re-evaluation of knowledge regarding correlates of protection.

    Conclusions:

    • The effectiveness of 4CMenB in infants supports its utility in preventing meningococcal serogroup B disease.
    • Phenotypic and genotypic data from invasive cases are crucial for understanding vaccine correlates of protection.
    • Further research is needed to refine correlates of protection for meningococcal vaccines.